Cagrilintide vs Tesofensine
Head-to-head comparison of Cagrilintide and Tesofensine for research applications. Both peptides are studied for various research applications, but they differ significantly in mechanism and evidence level.
Side-by-Side Comparison
| Attribute | Cagrilintide | Tesofensine |
|---|---|---|
| Category | Metabolic / Amylin Analog | Weight Loss / Reuptake Inhibitor |
| Mechanism | Cagrilintide activates amylin receptors (calcitonin receptor + RAMP complexes) in the area postrema and other hindbrain regions, promoting meal-related satiety through distinct pathways from GLP-1 agonism. | Tesofensine inhibits the presynaptic reuptake of serotonin, norepinephrine, and dopamine, increasing synaptic concentrations of all three monoamines. |
| Evidence Rating | B — Phase III / NDA Filed | C — Phase II–III Clinical Trials |
| Clinical Status | Phase 3 (REDEFINE program). NDA filed with FDA in 2026 for CagriSema. | Phase 3 clinical trials (Saniona). Phase 2 completed with significant weight loss results. |
| Safety Profile | GI adverse events: 79.6% in CagriSema group vs 39.9% placebo (nausea, vomiting, diarrhea, constipation); GI events mainly transient and mild-to-moderate | Phase 2 trials reported increased heart rate (5-8 bpm) and blood pressure elevation at higher doses; Common side effects: dry mouth, insomnia, constipation, nausea, diarrhea |
| Molecular Weight | N/A | ~397.5 g/mol |
| Half-Life | ~7 days (allows once-weekly dosing) | N/A |
Overview
Cagrilintide and Tesofensine are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, and safety profiles to help researchers understand the key differences and overlaps.
Cagrilintide — Mechanism & Evidence
Cagrilintide is a long-acting synthetic analog of human amylin, a peptide hormone co-secreted with insulin by pancreatic beta cells. It is being developed by Novo Nordisk both as a standalone agent and in fixed-dose combination with semaglutide (CagriSema). The CagriSema combination targets complementary appetite pathways — amylin acts on hindbrain satiety circuits while GLP-1 acts on hypothalamic and gut pathways. Novo Nordisk filed for FDA approval in 2026.
Key claims: CagriSema achieves ~20% weight loss; Superior to semaglutide alone; Standalone weight loss efficacy.
Tesamorelin 10mg
10mg
Tesofensine — Mechanism & Evidence
Tesofensine is a triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine) originally developed for Alzheimer's and Parkinson's disease. The compound was developed by NeuroSearch A/S and later licensed to Saniona, which is pursuing Phase 3 trials.
Key claims: Produces significant weight loss (~10% body weight); Suppresses appetite and reduces caloric intake; Increases resting metabolic rate.
Shared Research Applications
These peptides target different research areas. Cagrilintide focuses on Weight Management, Metabolic Health, while Tesofensine targets Weight Loss, Appetite Suppression.
Safety Considerations
Cagrilintide: GI adverse events: 79.6% in CagriSema group vs 39.9% placebo (nausea, vomiting, diarrhea, constipation) GI events mainly transient and mild-to-moderate Similar safety profile to GLP-1 class: pancreatitis risk, gallbladder events, thyroid C-cell tumors in rodents
Tesofensine: Phase 2 trials reported increased heart rate (5-8 bpm) and blood pressure elevation at higher doses Common side effects: dry mouth, insomnia, constipation, nausea, diarrhea Psychiatric effects reported: anxiety, mood changes (consistent with monoamine reuptake inhibitors)
Shop Research Peptides
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Tesofensine: Triple Monoamine Reuptake Inhibitor in Metabolic Research
Tesofensine triple monoamine reuptake inhibitor metabolic research preclinical evidence mechanisms safety
Cagrilintide Research: What Is Cagrilintide and How Does It Work?
Research review of Cagrilintide, a dual amylin and calcitonin receptor agonist, covering mechanism, preclinical data, and safety.
Cagrilintide-Semaglutide May Aid Type 2 Diabetes Glycemic Control
A combination of cagrilintide and semaglutide could improve glycemic control in patients with type 2 diabetes who are already using basal insulin, according to a report from Docwire News. The finding suggests a potential new treatment option for managing blood sugar levels in this patient population.